PDF
Corrigendum | Open Access
Stefania Gorini, Antonella De Angelis, Liberato Berrino, Natalia Malara, Giuseppe Rosano, Elisabetta Ferraro, "Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”", Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 9601435, 1 page, 2019. https://doi.org/10.1155/2019/9601435
Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
Stefania Gorini
,1 Antonella De Angelis,2 Liberato Berrino,2 Natalia Malara,3 Giuseppe Rosano,1,4 and Elisabetta Ferraro11Laboratory of Pathophysiology of Cachexia and Metabolism of Skeletal Muscle, IRCCS San Raffaele Pisana, 00166 Rome, Italy
2Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
3Bionem Laboratory, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy
4Cardiovascular and Cell Sciences Institute, St George’s, University of London, Cranmer Terrace, London, UK
In the article titled “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib” [1], the author Giuseppe Rosano should have been affiliated to the first and fourth affiliations. The corrected authors’ list is shown above.
References
- S. Gorini, A. De Angelis, L. Berrino, N. Malara, G. Rosano, and E. Ferraro, “Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 7582730, 15 pages, 2018. View at: Publisher Site | Google Scholar
Copyright
Copyright © 2019 Stefania Gorini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
